Soros Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Soros Fund Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,000	Closed	-$14.4M	–	216
2024 Q1	$14.4M	Sell	15,000 -2,500	-14%	-$2.38M	0.24%	101
2023 Q4	$15.4M	Buy	+17,500	New	+$14.4M	0.2%	115
2016 Q4	–	Sell	-1,381	Closed	-$555K	–	280
2016 Q3	$555K	Buy	+1,381	New	+$554K	0.01%	162

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Soros Fund Management's REGN Position: Q2 2024 in Review

Soros Fund Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 15,000 shares — an estimated $14.4M sold.

Soros Fund Management first reported a position in REGN in Q3 2016 and held it in 3 quarters. The position peaked at $15.4M in Q4 2023. 1,331 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

Soros Fund Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Soros Fund Management sold 15,000 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $14.4M.
Soros Fund Management first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 3 quarters.
Soros Fund Management's Regeneron Pharmaceuticals position peaked at $15.4M in Q4 2023.
1,331 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Soros Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.